Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
AI, aromatase inhibitors
Aromatase inhibitors
Breast cancer
ER, estrogen receptor
Sema4D, Semaphorin 4D
Semaphorin 4D
Tamoxifen
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
22
01
2019
revised:
01
04
2019
accepted:
03
04
2019
entrez:
24
4
2019
pubmed:
24
4
2019
medline:
24
4
2019
Statut:
epublish
Résumé
Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive breast cancers. Tamoxifen exerts ER-agonistic effects on bone, whereas AI negatively affect bone health by increasing resorption and fracture risk. The effect of endocrine therapies on circulating Sema4D levels in breast cancer patients has not been investigated yet. We measured circulating Sema4D plasma levels at primary diagnosis and in a follow-up sample 12 months after surgery in a cohort of 46 pre- and postmenopausal women with primary estrogen receptor positive breast cancer receiving adjuvant tamoxifen or AI. The mean baseline levels ± SD for Sema4D were 441.6 ± 143.4 pmol/l. No significant differences in total plasma Sema4D were observed when stratifying the patients according to age, menopausal status, tumor subtype, nodal and hormone receptor status, or tumor size. However, Sema4D levels were significantly reduced by 28% ( This finding potentially represents an additional mechanism of the bone-protective properties of tamoxifen and further emphasizes a link between Sema4D and estrogen receptor signaling.
Sections du résumé
BACKGROUND
BACKGROUND
Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive breast cancers. Tamoxifen exerts ER-agonistic effects on bone, whereas AI negatively affect bone health by increasing resorption and fracture risk. The effect of endocrine therapies on circulating Sema4D levels in breast cancer patients has not been investigated yet.
METHODS
METHODS
We measured circulating Sema4D plasma levels at primary diagnosis and in a follow-up sample 12 months after surgery in a cohort of 46 pre- and postmenopausal women with primary estrogen receptor positive breast cancer receiving adjuvant tamoxifen or AI.
RESULTS
RESULTS
The mean baseline levels ± SD for Sema4D were 441.6 ± 143.4 pmol/l. No significant differences in total plasma Sema4D were observed when stratifying the patients according to age, menopausal status, tumor subtype, nodal and hormone receptor status, or tumor size. However, Sema4D levels were significantly reduced by 28% (
CONCLUSION
CONCLUSIONS
This finding potentially represents an additional mechanism of the bone-protective properties of tamoxifen and further emphasizes a link between Sema4D and estrogen receptor signaling.
Identifiants
pubmed: 31011525
doi: 10.1016/j.jbo.2019.100237
pii: S2212-1374(19)30011-9
pii: 100237
pmc: PMC6461588
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100237Références
Nat Rev Cancer. 2002 Aug;2(8):584-93
pubmed: 12154351
J Bone Miner Res. 2003 Mar;18(3):473-81
pubmed: 12619932
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22
pubmed: 16754882
Oncologist. 2006 Jun;11(6):553-62
pubmed: 16794235
Br J Pharmacol. 2007 Jun;151(3):384-95
pubmed: 17420779
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5
pubmed: 18024597
Clin Interv Aging. 2007;2(1):55-64
pubmed: 18044075
J Clin Oncol. 2008 Mar 1;26(7):1051-7
pubmed: 18309940
Breast. 2009 Jun;18(3):159-64
pubmed: 19364653
Breast Cancer Res. 2011 Mar 14;13(2):205
pubmed: 21457526
Onco Targets Ther. 2010 Dec 17;4:1-11
pubmed: 21552410
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Nat Med. 2011 Oct 23;17(11):1473-80
pubmed: 22019888
PLoS One. 2011;6(10):e26627
pubmed: 22046317
Clin Interv Aging. 2014 Aug 28;9:1437-52
pubmed: 25210448
Expert Opin Ther Targets. 2015 Mar;19(3):299-306
pubmed: 25395071
Cancer Immunol Res. 2015 Jun;3(6):689-701
pubmed: 25614511
Bonekey Rep. 2015 May 20;4:692
pubmed: 26029361
Oncol Rep. 2015 Aug;34(2):1049-57
pubmed: 26035216
PLoS One. 2016 Feb 24;11(2):e0150151
pubmed: 26910109
Onco Targets Ther. 2016 Sep 26;9:5737-5750
pubmed: 27729799
Braz J Med Biol Res. 2017 Feb 20;50(3):e6057
pubmed: 28225892
Breast Cancer Res Treat. 2017 Aug;164(3):737-743
pubmed: 28526959
Blood Cancer J. 2018 May 11;8(5):42
pubmed: 29748532
Front Endocrinol (Lausanne). 2018 Jun 19;9:322
pubmed: 29971044
Bone Miner. 1993 Aug;22(2):87-94
pubmed: 8251768